Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab,
the safety will be investigated in previously untreated patients with low-grade B-cell
non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell lymphoma (MCL), and the safety and
tolerability will be investigated in patients with recurrent/refractory diffuse large B-cell
lymphoma (DLBCL).